NeuShen Therapeutics announced today it has entered into a license agreement with Hangzhou HealZen Therapeutics for a pre-clinical candidate compound for the treatment of central nervous system (CNS) diseases. Under the terms of the agreement, NeuShen Therapeutics will obtain the exclusive global development, registration, and commercialization rights of the compound, whose potential indications include epilepsy, mood disorders, etc. Drawing on its extensive experience in the field of CNS drug research & development, NeuShen is committed to rapidly advancing this project to the clinical development stage to bring safe and effective new treatments to patients.

“We are delighted to enter into this collaboration with HealZen,” said Joan Huaqiong Shen, founder and CEO of NeuShen. “We will continue the full range of pre-clinical research and development. We will formulate and execute our clinical development strategy based on the characteristics of the compound and the clinical needs of the target indication. This project will further strengthen our pipeline to target psychiatric disorders.”

"We are honored and pleased to have entered into this partnership with NeuShen," said Dr. Xinglu Zhou, co-founder and CEO of HealZen. " HealZen has always been committed to the research and development of new therapeutic drugs, with cutting-edge technology as the core driving force. This collaborative project is a showcase of the output of our small molecule drug development platform."

With the change in global population structure and the acceleration of population aging, CNS diseases have become a major health and social concern for nations worldwide. CNS diseases affect a large number of patients and place a heavy burden on society and families. Since its inception, NeuShen has been committed to making a meaningful impact on the lives of patients suffering from CNS diseases.

About NeuShen

NeuShen Therapeutics is a biotechnology company focusing on innovative drug research and development to address central nervous system disorders, using a dual platform approaches including AAV-based gene therapy and small molecule discovery. With operations both in Shanghai, China and Boston, MA, NeuShen has a world-class team and is honored to be advised by an outstanding Board of Directors and Scientific Advisory Board.

About Hangzhou HealZen Therapeutics

Hangzhou HealZen Therapeutics is an innovative drug research and development company that targets unmet clinical needs in oncology, autoimmune and central nervous system diseases. With cutting-edge technology as the core driving force, HealZen owns the self-developed DaMLib® drug-like fragment library, protein degradation drug DaTProD® and protein rescue drug DaTProS® technology platform, supporting the efficient and continuous output of high-quality new drug molecules.